Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis

Journal of Clinical Microbiology
Annika KrüünerF Drobniewski

Abstract

The objectives of this study were to (i) compare agreement of the MGIT 960 system for first-line drugs with a methodology (the resistance ratio method [RRM]) that had been used in clinical trials, relating drug susceptibility to clinical outcome; (ii) compare the performance of the MGIT 960, RRM, and microtiter plate assay (MPA) methodologies for second-line drug testing; and (iii) define critical concentrations for ciprofloxacin and moxifloxacin for liquid-culture-based testing. The large collection of clinical isolates of Mycobacterium tuberculosis (n = 247) used included 176 (71%) multidrug-resistant isolates. The results for MGIT 960 and the RRM for rifampin and isoniazid (n = 200) were in excellent (99 to 100%) agreement for all strains. For streptomycin, 97% of the results at the critical concentration and 92% at high concentration, and for pyrazinamide 92% of results overall, were concordant, but for ethambutol, fewer than 85% (65% for the critical concentration and 84% for the high concentration) of the MGIT-based results were concordant with those for the RRM. The MGIT 960, RRM, and MPA assays (n = 133) correlated well for most second-line drugs tested. For susceptibility to ofloxacin, the MGIT 960 and MPA results were...Continue Reading

References

Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·C Dye, B G Williams
Aug 30, 2001·Journal of Clinical Microbiology·A KrüünerG Källenius
May 31, 2002·Journal of Clinical Microbiology·Olga S ToungoussovaDominique A Caugant
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Yanmin HuDenis A Mitchison
May 22, 2003·Tuberculosis·Marcos A Espinal
Jun 5, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I MokrousovO Narvskaya
Jul 3, 2003·The Lancet Infectious Diseases·Amy Sarah GinsburgWilliam R Bishai
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·Deneke H MariamDan I Andersson
Jan 25, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y BalabanovaF Drobniewski

❮ Previous
Next ❯

Citations

Nov 15, 2007·Current Neurology and Neuroscience Reports·Thomas F Byrd, Larry E Davis
Jun 15, 2010·The Journal of Antimicrobial Chemotherapy·Kwok Chiu ChangRaphael Chiu Yeung Chan
Feb 24, 2012·The Journal of Antimicrobial Chemotherapy·Frederick A SirgelErik C Böttger
Apr 7, 2007·Current Opinion in Pulmonary Medicine·Jennifer Furin
Feb 2, 2012·Genome Research·Nicola CasaliFrancis Drobniewski
Mar 5, 2008·Antimicrobial Agents and Chemotherapy·Pontus JuréenSven Hoffner
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Sung Jae Shin, Michael T Collins
Oct 29, 2008·Antimicrobial Agents and Chemotherapy·Nicole RitzNigel Curtis
Oct 19, 2011·The European Respiratory Journal·Alena SkrahinaMatteo Zignol
Jun 8, 2007·Emerging Infectious Diseases·N Sarita ShahJ Peter Cegielski
Jan 28, 2014·Nature Genetics·Nicola CasaliFrancis Drobniewski
Apr 23, 2013·Tuberculosis Research and Treatment·Hyejin KimSungweon Ryoo
Feb 12, 2013·Bulletin of the World Health Organization·Alena SkrahinaMatteo Zignol
Apr 3, 2016·Diagnostic Microbiology and Infectious Disease·Zenda L BerradaEdward Desmond
Aug 3, 2010·Infectious Disease Clinics of North America·Keertan DhedaMartin P Grobusch
Mar 7, 2007·Diagnostic Microbiology and Infectious Disease·Claudio PiersimoniLuigi Codecasa
Sep 1, 2015·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Yanina BalabanovaFrancis Drobniewski
Jul 15, 2015·Tuberculosis·Olga IgnatyevaFrancis A Drobniewski
Mar 24, 2015·Tuberculosis·S TheeH S Schaaf
Apr 12, 2011·Tuberculosis·Ashwin S DharmadhikariEdward A Nardell
Jul 6, 2013·Asian Pacific Journal of Tropical Medicine·Gomathi SivaramakrishnanVanaja Kumar
Feb 27, 2015·International Journal of Antimicrobial Agents·Ximena GonzaloFrancis Drobniewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.